ChiCTR1800020096: A prospective, multi-center, single-arm clinical study for the efficacy and safety of dasatinib in the treatment of patients with unsuccessful imatinib desmoid tumor therapy. |
|
|
| Not yet recruiting | N/A | 51 | | pharmacotherapy 50mg/2 times/d | Peking University Cancer Hospital; Peking University Cancer Hospital, ChiaTai Tian Qqing Pharmaceutical Group Co., Ltd.(CTTQ) | Desmoid Tumor | | | | |
NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
|
| Recruiting | N/A | 258 | RoW | Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Gastrointestinal Stromal Tumors | 01/26 | 01/27 | | |
